Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer

Archives of Medical Research

Volumn 42, Issue 8, 2011, Pages 669-676

  Tan, Cong ^a   Xu, He Yun ^b   Zhang, Chen Ye ^a   Zhang, Hu ^b   Chen, Chun Mei ^a   Zhang, Wei Min ^b   Sun, Xiao Yu ^a   Jin, Yong Tang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

CDKN2A methylation; CYP1A1; GSTM1; Non small cell lung cancer (NSCLC); Polymorphism; TP53 mutation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE M1; MSPI PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADENOSQUAMOUS LUNG CANCER; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA ISOLATION; DNA METHYLATION; EXON; FEMALE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOCHROME P-450 CYP1A1; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863183405     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.11.008     Document Type: Article

References (36)

1. Alberg A.J., Ford J.G., Samet J.M. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines, 2nd ed. Chest 2007, 132:29S-55S.
2. Shi X., Zhou S., Wang Z., et al. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 2008, 59:155-163.
3. Risch A., Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008, 123:1-7.
4. Kawajiri K., Eguchi H., Nakachi K., et al. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996, 56:72-76.
5. Matsuzoe D., Hideshima T., Iwasaki A., et al. Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. Carcinogenesis 2001, 22:1327-1330.
6. Chan E.C., Lam S.Y., Fu K.H., et al. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 2005, 162:10-20.
7. Tsuda H., Hashiguchi Y., Nishimura S., et al. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003, 91:476-485.
8. Seike M., Gemma A., Hosoya Y., et al. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clin Cancer Res 2000, 6:4307-4313.
9. Sanchez-Cespedes M., Reed A.L., Buta M., et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999, 18:5843-5849.
10. Vonlanthen S., Heighway J., Tschan M.P., et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998, 17:2779-2785.
11. Karsai S., Abel U., Roesch-Ely M., et al. Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol 2007, 211:314-322.
12. Lee M., Sup H.W., Kyoung K.O., et al. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract 2006, 202:415-424.
13. Taghavi N., Biramijamal F., Sotoudeh M., et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer 2010, 10:138.
14. Peterson E.J., Bogler O., Taylor S.M. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 2003, 63:6579-6582.
15. Lin R.K., Wu C.Y., Chang J.W., et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010, 70:5807-5817.
16. Zhang J., Pickering C.R., Holst C.R., et al. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 2006, 66:10325-10331.
17. Jin Y., Zhang C., Xu H., et al. Combined effects of serum trace metals and polymorphisms of CYP1A1 or GSTM1 on non-small cell lung cancer: a hospital based case-control study in China. Cancer Epidemiol 2011, 35:182-187.
18. Jin Y., Xu H., Zhang C., et al. Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on nonsmall cell lung cancer: a hospital-based case-control study in China. BMC Cancer 2010, 10:422.
19. Le Calvez F., Mukeria A., Hunt J.D., et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005, 65:5076-5083.
20. Liu Y., Gao W., Siegfried J.M., et al. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 2007, 7:74.
21. Toyooka S., Tokumo M., Shigematsu H., et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006, 66:1371-1375.
22. Goto I., Yoneda S., Yamamoto M., et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996, 56:3725-3730.
23. Przygodzki R.M., Bennett W.P., Guinee D.J., et al. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics 1998, 8:503-511.
24. Gao W.M., Mady H.H., Yu G.Y., et al. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 2003, 40:141-150.
25. Bumroongkit K., Rannala B., Traisathit P., et al. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. Cancer Genet Cytogenet 2008, 185:20-27.
26. Jarmalaite S., Kannio A., Anttila S., et al. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003, 106:913-918.
27. Kim D.H., Nelson H.H., Wiencke J.K., et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001, 61:3419-3424.
28. Ng C.S., Zhang J., Wan S., et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 2002, 79:101-106.
29. Liu Y., An Q., Li L., et al. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 2003, 24:1897-1901.
30. Toyooka S., Suzuki M., Tsuda T., et al. Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 2004, 110:462-464.
31. Kinoshita I., Dosaka-Akita H., Mishina T., et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996, 56:5557-5562.
32. Geradts J., Fong K.M., Zimmerman P.V., et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999, 5:791-800.
33. Leong W.F., Chau J.F., Li B. p53 Deficiency leads to compensatory up-regulation of p16INK4a. Mol Cancer Res 2009, 7:354-360.
34. Yamakoshi K., Takahashi A., Hirota F., et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol 2009, 186:393-407.
35. Wang Y., Zhang Z., Kastens E., et al. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res 2003, 63:4389-4395.
36. van Bladeren P.J. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 2000, 129:61-76.